Harmony Biosciences Holdings, Inc. · NASDAQ:HRMY
Harmony Biosciences — Q2 2022 Earnings Presentation
10 slides from Harmony Biosciences's earnings presentation, Aug 2, 2022
Slide 1: Q2 2022 Financial and Business Update
Harmony Biosciences Q2 2022 Financial and Business Update August 2, 2022
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc
Slide 3: Harmony's Strategy for Growth
Harmony’s Strategy for Growth Expand Optimize Acquire Clinical WAKIX ® New Utility of Performance Assets WAKIX 3
Slide 4: Q2 2022 WAKIX Net Revenue Performance
Q2 2022 WAKIX® Net Revenue Performance Q2 2022 Net Revenue of $107.0M 45% ∆ 2Q22 ∆ 2Q22 2Q21 1Q22 2Q22 vs. 1Q22 vs. 2Q21 $107.0 $73.8 $85.3 $107.0 25% 45% $73.8 Strong Revenue Growth ▪ 45% growth Q2 2022 vs. Q2 2021 ▪ 25% growth Q2 2022 vs. Q1 2022 ▪ Strong momentum in top line prescription Q2 2021
Slide 5: Driving Growth Through Our Launch For WAKIX
Driving Growth Through Our Launch For WAKIX® Q2 2022 Performance ~75% In-Person Access to HCPs Average # of ~4,300 WAKIX Patients Patient Outreach Programs & Support Continued Growth in Depth & Breadth of Prescriber Base Healthcare Professional Educational Initiatives Managed Care >80% U.S. Covered
Slide 6: Harmony Development Pipeline
Harmony Development Pipeline Regulatory Marketed Upcoming Product / Indication Pre-IND Phase 1 Phase 2 Phase 3 Filing(1) Product Milestones WAKIX® EDS in Narcolepsy (Adults) Cataplexy in Narcolepsy (Adults) Pitolisant Pediatric Trial completed Narcolepsy(2) Idiopathic Trial initiated Hypersomnia (IH
Slide 7: Financial Highlights
Financial Highlights (In millions, USD) Three Months Ended Six Months Ended June 30, 2022 June 30, 2022 45% 44% $192.3 Net Product $107.0 $133.5 $73.8 Revenues Q2 2021 Q2 2022 1H 2021 1H 2022 74% 59% Non-GAAP $65.8 Adjusted Net $34.7 $37.9 Income(1) $21.9 Q2 2021 Q2 2022 1H 2021 1H 2022 $234.3 $258.
Slide 8: Q2 2022 Financial Summary
Q2 2022 Financial Summary (In millions, USD) Three Months Ended June 30, % Change 2022 2021 Net Product Revenues $107.0 $73.8 45% Cost of Product Sold 18.9 12.7 49% Total Operating Expenses $55.0 $37.8 45% R&D Expense 12.7 6.5 95% S&M Expense 20.2 17.0 18% G&A Expense 22.2 14.3 55% Net Income $23.5
Slide 9: Q2 2022 GAAP vs Non-GAAP Reconciliation
Q2 2022 GAAP vs Non-GAAP Reconciliation (In millions, USD) Three Months Ended June 30, 2022 2021 GAAP net income $23.5 $14.1 Non-cash interest expense(1) 0.4 0.7 Depreciation 0.1 0.1 Amortization(2) 6.0 4.6 Stock-based compensation expense 7.4 3.8 Income tax effect related to Non-GAAP adjustments(3)
Slide 10: Thank You
HARMONY BIOSCIENCES Thank You
Harmony Biosciences Holdings — Q2 2022 Earnings Presentation on 6ix